BPTF-IN-BZ1 is a BPTF (Bromodomain PHD Finger Transcription Factor) inhibitor, with a high potency (Kd = 6.3 nM).
GSK1379725A (AU1) is the first selective BPTF (Bromodomain PHD Finger Transcription Factor) ligand with a Kd of 2.8 uM, showing no binding activity for Brd4.
GSK1379725A (AU1) is the first selective BPTF (Bromodomain PHD Finger Transcription Factor) ligand with a Kd of 2.8 uM, showing no binding activity for Brd4.
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 can cross the blood-brain barrier, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has potential for research of brain neurogenesis and long-term memory function.
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 can cross the blood-brain barrier, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has potential for research of brain neurogenesis and long-term memory function.
3-O-Methyl-D-glucopyranose is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
Spinosyn A, a polyketide-derived macrolide produced by Saccharopolyspora spinosa, is a potent insecticide.
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has...
TAME hydrochloride is an inhibitor of anaphase-promoting complex/cyclosome (APC/C or APC), which binds to APC/C and prevents its activation by Cdc20 and Cdh1, produces mitotic arrest. TAME hydrochloride is not cell permeable.
JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation.
ML-SA5 is a potent TRPML1 cation channel agonist that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC50 of 285 nM and is more potent than ML-SA1. ML-SA5 has anticancer activity and can inhibit tumour growth.